Abstract
Goals
The aim of the study was to determine the feasibility and validity of a newly developed patient-based instrument—the Patient Neurotoxicity Questionnaire (PNQ)—for grading chemotherapy-induced peripheral neuropathy (CIPN).
Patients and methods
We prospectively collected data from 300 female patients who were treated with taxane chemotherapy for primary breast cancer as part of a national multicenter phase III randomized trial (N-SAS BC 02). We evaluated patient compliance with the PNQ and several validation parameters, including concordance between CIPN grades noted by physicians (National Cancer Institute Common Toxicity Criteria) and patients (PNQ), and the concurrent validity and responsiveness of the PNQ versus the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) utilizing data at pre-treatment and before three, five, and seven treatment cycles.
Main results
The questionnaire completion rate was >90% at all assessments. Evaluation by physicians always resulted in lower neuropathy assessment scores compared with those reported directly by patients (weighted kappa coefficients, 0.02–0.06). Both PNQ sensory and motor scores were significantly correlated with the FACT/GOG-Ntx (r = 0.66 and 0.51, respectively). In the repeated measures analysis of variance model, PNQ grades increased considerably as treatment continued, indicating progressively worsening CIPN over time.
Conclusions
The PNQ has an applicable degree of feasibility and validity, useful for the diagnosis of CIPN as well as for clinical treatment decision-making, where the development of CIPN is a potential treatment-limiting consideration. Physicians underreport and underestimate the severity of CIPN symptoms compared with patients, thereby supporting the importance of assessing patient-reported outcomes using the PNQ.
Similar content being viewed by others
References
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F, European Organization for Research and Treatment of Cancer Study Group on Quality of Life (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. doi:10.1093/jnci/85.5.365
Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147–159. doi:10.3109/07357909009017560
Basch E, Lasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909. doi:10.1016/S1470-2045(06)70910-X
Boehmke MM, Dickerson SS (2005) Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nurs 28:382–389. doi:10.1097/00002820-200509000-00008
Bonomi AE, Cella DF, Hahn EA, Bjordai K, Sperner-Unterweger B, Gangeri L, Bergman B, Willems-Groot J, Hanquet P, Zittoun R (1996) Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 5:309–320. doi:10.1007/BF00433915
Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741–748. doi:10.1111/j.1525-1438.2003.13603.x
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K, Lioyd S, Purl S, Blendowski C, Goodman M, Barnicle M, Stewart I, McHale M, Bonomi P, Kaplan E, IV TS, Thomas CR Jr, Harris J (1993) The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 11:570–579
Cohen J (1968) Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70:213–220. doi:10.1037/h0026256
Fayers PM, Machin D (2007) Scores and measurements: validity, reliability, sensitivity. Quality of life: the assessment, analysis, and interpretation of patient-reported outcomes, 2nd edn. Wiley, Chichester, pp 77–107
Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22:3485–3490. doi:10.1200/JCO.2004.03.025
Fumimoto H, Kobayashi K, Chang C-H, Eremenco S, Fujiki Y, Uemura S, Ohashi Y, Kudoh S (2001) Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual Life Res 10:701–709. doi:10.1023/A:1013851216181
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15–49. doi:10.1053/j.seminoncol.2005.12.010
Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a Gynecologic Oncology Group study. Int J Gynecol Cancer 17:387–393. doi:10.1111/j.1525-1438.2007.00794.x
Hughes RA (2002) Peripheral neuropathy. BMJ 324:466–469. doi:10.1136/bmj.324.7335.466
Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K, Shimozuma K (1999) Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8:355–363. doi:10.1002/(SICI)1099-1611(199907/08)8:4<355::AID-PON401>3.0.CO;2-I
Kuroi K, Shimozuma K (2004) Neurotoxicity of the taxanes: symptoms and quality of life assessment. Breast Cancer 11:92–99. doi:10.1007/BF02968010
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174. doi:10.2307/2529310
Lipscomb J, Reeve BB, Clauser SB, Abrams JS, Bruner DW, Burke LB, Denicoff AM, Ganz PA, Gondek K, Minasian LM, O’Mara AM, Revicki DA, Rock EP, Rowland JH, Sgambati M, Trimble EL (2007) Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol 25:5133–5140. doi:10.1200/JCO.2007.12.4644
Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran A, Wolmark N; NSABP Operations and Biostatistical Center, Pittsburgh, PA (2003) Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc Am Soc Clin Oncol 22. Abstract 12.
Ohsumi S, Sunada Y (2004) Techniques for the neurological examination of taxane-induced neuropathy. Breast Cancer 11:86–91. doi:10.1007/BF02968009
Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M (2006) Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42:1159–1166. doi:10.1016/j.ejca.2006.01.032
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R, EORTC Quality of Life Group (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135–1139. doi:10.1016/j.ejca.2005.02.012
Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509–513. doi:10.1023/A:1008345613594
Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739–744. doi:10.1023/A:1008344507482
Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17. doi:10.1007/PL00007853
Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, Morrow GR, Dueck AC (2007) Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-Sponsored Clinical Trials Networks. J Clin Oncol 25:5070–5077. doi:10.1200/JCO.2007.12.7670
Spearman C (1904) The proof and measurement of association between two things. Am J Psychol 15:72–101. doi:10.2307/1412159
Stephens RJ, Hopwood P, Girling DJ, Machin D (1997) Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Qual Life Res 6:225–236. doi:10.1023/A:1026458604826
Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27–46. doi:10.1111/j.1529-8027.2008.00156.x
Acknowledgements
We are grateful to all the patients who participated in this study and all investigators who enrolled patients into the trial. We also thank Yumiko Nomura for data management support and Michiko Kato for assistance with editing the manuscript. This study was mainly supported by the Comprehensive Support Project for Oncology Research (CSPOR) and the Comprehensive Support Project for Health Outcomes Research (CSP-HOR) established by the Public Health Research Foundation (PHRF) in Tokyo, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shimozuma, K., Ohashi, Y., Takeuchi, A. et al. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17, 1483–1491 (2009). https://doi.org/10.1007/s00520-009-0613-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-009-0613-7